Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
The data are positive, but might not do much for the company’s sales.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.